ProCE Banner Activity

Expert Answers to Pathologist Questions on New Biomarkers for Precision Therapy in Lung Cancer

Podcast Episodes
In this podcast episode, listen to Nathan Pennell, MD, PhD, a medical oncologist, and Laura J. Tafe, MD, a molecular pathologist, as they answer questions from a clinician audience on best practices when testing for actionable mutations in NSCLC.

Released: December 28, 2020

Share

Faculty

Nathan Pennell

Nathan Pennell, MD, PhD

Professor
Director,
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Laura J. Tafe

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Faculty Disclosure

Primary Author

Nathan Pennell, MD, PhD

Professor
Director,
Cleveland Clinic Lung Cancer Medical Oncology Program
Department of Hematology and Medical Oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio

Laura J. Tafe, MD

Associate Professor of Pathology and Laboratory Medicine
Associate Director, Laboratory for Clinical Genomics and Advanced Technology (CGAT)
Director, Molecular Oncology
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, New Hampshire